A Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.

Vivus

Status and phase: Completed; Phase 1

Conditions: Erectile Dysfunction

Treatments: Other: alcohol; Drug: avanafil

Study type: Interventional

Funder types: Industry

Identifiers

NCT01054859

TA-015

Details and patient eligibility

About

The purpose of this study is primarily to evaluate whether taking avanafil with alcohol causes the blood pressure to fall.

Full description

The trial is a single-centre double-blind, randomized, placebo-controlled, three-period, three-way crossover study, in which each subject will be randomized to receive each of the following three treatments with a washout period of at least 5 days between treatments:

• Treatment A: a single oral dose of one 200 mg avanafil tablet plus an oral dose of alcohol drink mixed with fruit juice (0.5 g of absolute ethanol per kilogram of body weight).
• Treatment B: a single oral dose of one placebo tablet plus an oral dose of alcohol drink mixed with fruit juice (0.5 g of absolute ethanol per kilogram of body weight).
• Treatment C: a single oral dose of one 200 mg avanafil tablet plus an oral dose of placebo drink mixed with fruit juice.

For each treatment period, Dinamap (or DataScope) automatic measurements of supine blood pressure and pulse rate will be taken pre-dose and every 15 minutes for 4 hours post-dose. Alcohol levels using a breathalyzer will be measured at pre-dose and up to 8 hours post dose during all 3 treatments by designated unblinded personnel. Subjects should be supine for at least 5-10 minutes before the blood pressure and heart rate measurement.

Enrollment: 15 patients

Sex: Male

Ages: 21 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult male subjects,
• either 21 to 45 years of age,
• must be medically healthy with no clinically significant screening results.

Exclusion criteria

• Major exclusion criteria include: history or clinical evidence of clinically relevant cardiovascular (including thromboembolic disorders), hepatic, renal, hematological, endocrine, pulmonary, gastrointestinal, psychiatric or neurological impairment; any clinically significant laboratory abnormalities as judged by the investigator; systolic blood pressure < 90 or >150 mmHg; diastolic blood pressure < 50 or > 95 mmHg;
• allergy to or previous adverse events with PDE5 inhibitors, alcohol or their constituents; use of prescription or over-the-counter drugs that are known to interfere with metabolism by the cytochrome P450 3A4 enzyme within 30 days of Day 1 dosing (Period 1);
• use of any investigational drug within 30 days of Day 1 dosing (Period 1);
• use of any prescription or over-the-counter drugs or herbal remedies within 14 days of Day 1 dosing (Period 1);
• history of alcohol or drug abuse within 18 months, history of smoking within 6 months; positive breath alcohol, positive cotinine test or positive urine drug screen at screening or on Day -1;
• positive serology for HIV, HCV, HBsAg. Additional exclusion criteria are listed in Section 4.2.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

15 participants in 3 patient groups

Treatment A

Experimental group

Description:

0.5 g/Kg alcohol plus 200 mg avanafil tablet

Treatment:

Drug: avanafil

Drug: avanafil

Treatment B

Active Comparator group

Description:

0.5 g/kg alcohol

Treatment:

Other: alcohol

Treatment C

Active Comparator group

Description:

200 mg avanafil tablet

Treatment:

Drug: avanafil

Drug: avanafil